Hepatitis C treatment of opioid dependants receiving maintenance treatment: Results of a Norwegian pilot study

European Addiction Research

Volumn 13, Issue 4, 2007, Pages 216-221

  Krook, Aud L ^a,d   Stokka, Dorthe ^a   Heger, Bernt ^b   Nygaard, Egil ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Clinic of Abuse and Dependence ^*

^d Clinic of Abuse and Dependence   (Norway)

Author keywords

Abstinence; Buprenorphine; Compliance; Depression; Hepatitis C; Interferon; Methadone; Platelet count; Ribavirin

Indexed keywords

ANTIDEPRESSANT AGENT; METHADONE; OPIATE; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEALTH PROGRAM; HEMATOLOGY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAINTENANCE THERAPY; MALE; NORWAY; OPIATE ADDICTION; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; REHABILITATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 34548663662     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104884     Document Type: Article

References (17)

1. Dalgard O, Jeansson K, Skaug N, Raknerud N, Bell H: Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003;38:864-870.
2. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26(suppl 1):2S-10S.
3. Krook A, Albert J, Andersson S, Biberfeld G, Blomberg J, Eklund I, Engstrøm A, Julander I, Käll K, Martin C, Stendahl P, Struve J, Sönnerborg A: Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:381-386.
4. Bell H, Hellum K, Harthaug S, Mæland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Prescott L, Simmonds P: Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group. Scand J Infect Dis 1996;28:357-359.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramandori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group: Peg-interferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-355.
6. Dalgard O, Bjøro K, Hellum K, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H: Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-1265.
7. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999;30:956-961.
8. Van Thiel D, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P: Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995;7;165-168.
9. Schaefer M, Schmidt F, Fowaczny C, Lorenz R, Martin G, Schindlbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K: Adherence and mental side effects during hepatitis C treatment with interferon α and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-451.
10. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN: The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005;29:159-165.
11. Neri S, Bruno CM, Abate G, Ierna D, Mauceri B, Cilio D, Bordonaro F, Pulvirenti D, Italiano C, Caruso L: Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002;24:1627-1635.
12. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G: A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-124.
13. Backmund M, Meyer K, Von Zielanka M, Eichenlaub D: Treatment of hepatitis C infection in injecting drug users. Hepatology 2001;34:188-193.
14. Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002;67:117-123.
15. Svanborg P, Åsberg M: A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord 2001;64:203-216.
16. Krook A, Brørs O, Dahlberg J, Grouff K, Magnus P, Røysamb E, Waal H: A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 2002;97:533-542.
17. Caliceti P: Pharmacokinetics of pegylated interferons: what is misleading? Dig Liver Dis 2004;36(suppl 3):S334-S339.